Keywords: India, Obesity, Tuberculosis, Rimonabant, Sanofi-Aventis

Indian Health Ministry bans obesity drug rimonabant following reports of side effects; TB drug curb moves “a failure”

Article | 04 January 2010

After almost 10 months since India’s Drugs Technical Advisory Board (DTAB) recommended its prohibition following reports of various side effects, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Aventis

Aventis Pharma

Sanofi-Aventis

Go to company listing

Related Drugs

Benadryl

Diphenhydramine

Dexfenfluramine

Redux

Go to drug listing